[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"intra-cerebral-hemorrhage\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:intra-cerebral-hemorrhage":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,41,63,90,120],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100565914","maximal-medical-treatment-of-intracerebral-haemorrhage-pilot-trial---max-ich-pilot-trial-100565914",false,"NCT06648369","Maximal Medical Treatment of Intracerebral Haemorrhage Pilot Trial - MAX-ICH Pilot Trial","MAX-ICH","Inclusion Criteria:\n\n* Symptomatic imaging proven diagnosis of non-traumatic ICH\n* Vascular imaging (MR-\u002FCT-angiogram or DSA) on admission to rule out high suspicion of macrovascular bleeding source\n* Enrolment no later than 6 hours of symptom onset\n* Age \\>18 years, no upper age limit\n* Informed consent as documented by signature or fulfilling the criteria for emergency consent\u002F deferral consent\n\nExclusion Criteria:\n\n* Palliative care\u002Fcomfort therapy decision in the emergency department\n* ICH due to trauma (major head trauma \\\u003C24 hours of symptom onset causing loss of consciousness and thought to be sufficient to have caused the intracerebral bleeding)\n* High suspicion of ICH due to arteriovenous malformation (AVM), aneurysm or sinus-venous-thrombosis confirmed by neuroimaging, brain tumor, vasculitis, RCVS\u002FPRES or system disease (liver disease, inherit coagulopathy)\n* Severe ICH (haematoma volume \\>60ml or GCS \\\u003C8)\n* Haematoma evacuation or decompressive craniectomy within 72 hours planned or highly likely (isolated EVD is not an exclusion criterion)\n* Severe pre-morbid disability \\[modified Rankin scale (mRS) is ≥4\\]\n* Contraindication against the use of tranexamic acid\n* Active participation in another drug or devices trial concurrently\n* Female patient that are either pregnant or breastfeeding\n* Contraindications against Clevidipine (allergy to soja, lipid metabolism defect or known severe aortic stenosis)","ALL","18 Years","100 Years",{"count":20,"type":21},50,"ESTIMATED","INTERVENTIONAL",[24],"NA","The MAX-ICH pilot trial is a phase-II study aimed at assessing the feasibility and safety of a comprehensive care bundle for patients with intracerebral hemorrhage (ICH). This \"maximal medical treatment\" approach combines advanced interventions like intensive blood pressure control, rapid anticoagulation reversal, and tranexamic acid administration to potentially improve outcomes. The primary objective is to evaluate recruitment feasibility over 12 months, while secondary objectives include protocol adherence, safety monitoring, and the exploration of clinical outcomes. The study focuses on the critical first 72 hours of care to determine if this approach can be effectively implemented in clinical practice.",[27],"Intra Cerebral Hemorrhage","RECRUITING","2026-06-30",{"date":31,"type":32},"2026-07-02","ACTUAL",{"date":34,"type":32},"2025-08-07",{"date":36,"type":21},"2028-11-30",{"name":38,"class":39},"Insel Gruppe AG, University Hospital Bern","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":50,"phases":4,"briefSummary":51,"conditions":52,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":62},"100361777","recovery-of-consciousness-following-intracerebral-hemorrhage-100361777","NCT03990558","Recovery of Consciousness Following Intracerebral Hemorrhage","RECONFIG","Inclusion Criteria:\n\n* 18 years or older.\n* Diagnosis of primary ICH (i.e., related to hypertension or anticoagulants) on Head CT and\u002For MRI in the frontal lobe, thalamus, or striatocapsular region.\n* Unresponsive to commands within 48 hours after onset of the bleed.\n* English, Spanish or, French as the primary language.\n\nExclusion Criteria:\n\n* Major bleeding in the cortex outside of the frontal lobe, cerebellum, or brainstem (judged as a cause for unconsciousness as per the attending neurointensivist).\n* Other causes of ICH or different types of acute brain injury (e.g., traumatic brain injury).\n* Severe cardiorespiratory compromise and similar acutely life-threatening conditions at the time of enrollment.\n* Evidence of pre-morbid aphasia or deafness.\n* Unconscious prior to ICH.\n* Pregnancy.\n* Prisoners.\n* Health care proxy decides against study participation or decided for withdrawal of life sustaining therapies.",{"count":49,"type":21},150,"OBSERVATIONAL","The objectives of the RECONFIG clinical study are to :\n\n1. To identify the time to the first diagnosis of cognitive motor dissociation (CMD) in intracerebral hemorrhage (ICH) patients and to investigate whether these patients will clinically follow commands earlier after the hemorrhage.\n2. To determine whether CMD independently predicts long term functional outcomes (6-month mRS scores) in ICH patients, and is associated with long term cognitive and quality of life outcomes.\n3. To determine the EEG response to verbal commands of the motor imagery paradigm between patients with and without sensory aphasia.\n\nThe overall goal is to determine predictors and the trajectory of neurological recovery.",[27],"2026-05-11",{"date":55,"type":32},"2026-05-13",{"date":57,"type":32},"2019-06-15",{"date":59,"type":21},"2031-03-31",{"name":61,"class":39},"Columbia University",2,{"id":64,"slug":65,"hasResults":11,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":69,"eligibilityCriteria":70,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":71,"targetDuration":4,"studyType":22,"phases":73,"briefSummary":74,"conditions":75,"keywords":77,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":40},"100410196","influence-of-cerebral-oedema-in-intracerebral-haemorrhage-100410196","NCT04621357","Influence of Cerebral Oedema in Intracerebral Haemorrhage","Consequences of Oedema on the Prognosis of InTraCerebral Haemorrhage","COPITCH","Inclusion Criteria:\n\n* With a spontaneous ICH, i.e. non traumatic\n* Admitted within 12 hours of stroke onset. For wake-up strokes, time of last seen well will be considered as stroke onset\n* Patient insured under the French social security\n* Consent form signed\n\nExclusion Criteria:\n\n* Pure intraventricular haemorrhages\n* \"secondary\" ICH: ICH resulting from intracranial vascular malformation, intracranial venous thrombosis, head trauma or tumour; haemorrhagic transformation within an infarct\n* Pre-admission modified Rankin score of 4 or 5\n* Life expectancy of less than 1 year related to comorbidities (end stage cancer, end stage organ failure)\n* Pregnancy or breastfeeding or Women of childbearing age without effective contraception (a pregnancy test will be done)\n* Adults who are deprived of their liberty by judicial or administrative decision\n* Referral from other hospitals\n* Contra-indication to MRI : claustrophobia, ocular metallic foreign bodies (accidental or other) or in a risk area (nervous or vascular system);irremovable implanted medical device (pacemaker, neurostimulator, cochlear implants and others);metallic heart valve (mainly old heart valves) or vascular clips previously implanted on cranial aneurysms; gadolinium allergy\n* No consent form",{"count":72,"type":21},500,[24],"In 2020, IntraCerebral Haemorraghe (ICH) remains the most devastating type of stroke. Besides stroke unit care, no specific treatment has been proven effective yet. Perihaematomal oedema (PHO) could be a promising therapeutic target. However, the mechanisms, the natural history as well as the clinical impact of this PHO remain unclear. The COPITCH study has been designed to answer these questions",[76,27],"Stroke",[27,78,79,80],"Perihaematomal oedema","MRI","outcome","2026-04-17",{"date":83,"type":32},"2026-04-22",{"date":85,"type":32},"2021-06-04",{"date":87,"type":21},"2027-12-03",{"name":89,"class":39},"University Hospital, Lille",{"id":91,"slug":92,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":4,"eligibilityCriteria":96,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":97,"targetDuration":99,"studyType":50,"phases":4,"briefSummary":100,"conditions":101,"keywords":106,"overallStatus":110,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":40},"100620139","cerebral-arteriovenous-malformation-with-aneurysm-epidemiology-clinical-features-and-prognosis-100620139","NCT07353736","Cerebral Arteriovenous Malformation With Aneurysm: Epidemiology, Clinical Features, and Prognosis","Hemodynamic Mechanisms, Clinical Profiles, and Prognostic Factors in Patients With Cerebral Arteriovenous Malformations and Intracranial Aneurysms: An Observational Cohort Study","Inclusion Criteria:\n\n* Patients diagnosed with cerebral arteriovenous malformation and intracranial aneurysm confirmed by CTA, MRA, and\u002For DSA;\n* Availability of complete clinical and imaging data;\n* Provision of written informed consent by the patient or their legally authorized representative to participate in the study and undergo follow-up;\n* Not concurrently participating in any other clinical trials that may interfere with the outcomes of this study.\n\nExclusion Criteria:\n\n* Previous complete occlusion of the aneurysm and\u002For arteriovenous malformation prior to enrollment;\n* Coexistence of other cerebrovascular diseases such as moyamoya disease, cerebral cavernous malformation, cerebral venous sinus thrombosis, etc.;\n* Absence of DSA imaging data or poor image quality that precludes accurate evaluation of key anatomical and hemodynamic parameters of the AVM and intracranial aneurysm.",{"count":98,"type":21},630,"2 Years","The study is a multicenter, prospective cohort study designed to assess the natural history, clinical safety and efficacy of various treatment strategies in patients with cerebral arteriovenous malformations (AVMs) and intracranial aneurysms.",[102,103,27,104,105],"Cerebral Arteriovenous Malformation","Intracranial Arterial Diseases","Intracranial Aneurysm","Brain Diseases",[107,108,109,102,104],"Hemodynamic Mechanisms","Prospective cohort study","Endovascular treatment","NOT_YET_RECRUITING","2026-01-17",{"date":113,"type":32},"2026-01-20",{"date":115,"type":21},"2026-02-01",{"date":117,"type":21},"2030-12-30",{"name":119,"class":39},"Duan Chuanzhi",{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":126,"eligibilityCriteria":127,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":128,"targetDuration":4,"studyType":22,"phases":130,"briefSummary":131,"conditions":132,"keywords":133,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":145},"100395877","ultra-early-minimally-invasive-intracerebral-haemorrhage-evacuation-versus-standard-treatment-100395877","NCT04434807","Ultra-Early, Minimally inVAsive intraCerebral Haemorrhage evacUATion Versus Standard trEatment","Ultra-Early, Minimally inVAsive intraCerebral Haemorrhage evacUATion Versus Standard trEatment (EVACUATE)","EVACUATE","Inclusion Criteria:\n\n1. Patients with an acute supratentorial intracerebral hemorrhage (ICH) ≥20mL in volume\n2. Age ≥18 years\n3. Surgery can commence within 8 hours of symptom onset (the time the patient was last known to be well) or, in patients with wake-up onset, within 8 hours of the time the patient awoke with symptoms. Patients presenting with small ICH (volume \\\u003C20mL) with clinical deterioration judged due to ICH hematoma expansion meeting volume criteria may be randomized if surgery can commence within 8 hours of clinical deterioration\n4. Moderate neurological deficit (NIHSS≥6)\n5. Pre-stroke mRS ≤3 (independent function or requiring only minor domestic assistance and able to manage alone for at least 1 week).\n6. CTA or MRA is performed and does not show an underlying vascular lesion\n\nExclusion Criteria:\n\n1. Brainstem ICH\n2. ICH secondary to trauma, where brain injury is judged more likely to be due to the broad effects of trauma rather than the focal ICH.\n3. Hereditary or acquired hemorrhagic diathesis or coagulation factor deficiency (in liver disease, INR\\>1.4).\n4. Platelet count \\\u003C75,000\n5. Unreversible heparinization or anticoagulation. If reversing warfarin, INR should be ≤1.4 before procedure commences. Reversal of heparin by protamine, dabigatran by idarucizumab and rivaroxaban, apixaban and enoxaparin by andexanet (where available) is permitted. Unreversed anticoagulation with a last dose within 48 hours is an exclusion.\n6. Recent (\\\u003C12 hours) parenteral GPIIb\u002FIIIa antagonist.\n7. Recent (\\\u003C1 hour) thrombolysis. If the ICH has occurred between 1 and 12 hours following thrombolysis, cryoprecipitate (1U per 10kg) and tranexamic acid must be administered prior to treatment.\n8. Participation in any investigational study in the last 30 days\n9. Pregnant women (clinically evident)\n10. Co-morbidities or advance care directive preventing general anaesthesia for the procedure.\n11. Known terminal illness such that the patients would not be expected to survive a year.\n12. Planned withdrawal of care or comfort care measures.\n13. Any condition that, in the judgment of the investigator could impose hazards to the patient if study therapy is initiated or affect the participation of the patient in the study.",{"count":129,"type":21},240,[24],"A randomized controlled trial of ultra-early, minimally invasive, hematoma evacuation versus standard care within 8 hours of intracerebral hemorrhage. Patients presenting to the emergency department with stroke due to supratentorial, spontaneous intracerebral hemorrhage \\>20mL volume will be assessed to determine their eligibility for randomization into the trial. If the patient gives informed consent they will be randomized 50:50 using central computerized allocation to minimally invasive hematoma evacuation using the Aurora surgiscope and evacuator (Integra Lifesciences) versus standard medical therapy. The trial is prospective, randomized, open-label, blinded endpoint (PROBE) design with seamless phase 2b-3 transition if the intermediate endpoint (successful hematoma evacuation) is met in analysis of the first 52 patients. Adaptive sample size re-estimation (Mehta and Pocock) will be performed when 160 patients have completed 6 month follow-up (minimum sample size 240, maximum sample size 434).",[27,76],[134,135],"neurosurgery","minimally invasive","2025-10-24",{"date":138,"type":32},"2025-10-28",{"date":140,"type":32},"2020-11-15",{"date":142,"type":21},"2028-12",{"name":144,"class":39},"University of Melbourne",13]